Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430427 · ClinicalTrials.gov registry record
Brain Networks and Mobility Function: B-NET
A clinical trial of White Matter Disease and Central Nervous System, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 192
- Enrollment target
- 1
- Study location
NCT03430427: Completed study of White Matter Disease and Central Nervous System, sponsored by Wake Forest University Health Sciences.
NCT03430427 is a study of White Matter Disease and Central Nervous System that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 192 participants, below the 4,050-participant average among 3 other White Matter Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03430427, a study of White Matter Disease and Central Nervous System, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 192 participants
- Enrollment target
- 1
- Study location
Study Summary
Rapidly accumulating evidence indicates that the central nervous system (CNS) plays a pivotal role in mobility function with age-associated CNS changes strongly contributing to declining mobility. Studies linking the brain to mobility have used anatomical measures like brain volume and white matter integrity, and suggest that damage to the connecting fibers of the brain (white matter) is related to mobility impairment. Unfortunately, age-related structural white matter damage appears irreversible and only indirectly indicates the functional connectivity between brain regions. It is believed that functional brain network analyses have the potential to identify individuals that may benefit from interventions prior to the development of irreversible white matter lesions. The current project will assess both physical and cognitive function and integrate these variables with measures of brain network connectivity.
Primary Outcome
The expanded Short Physical Performance Battery (eSPPB) is a modified version of a widely used assessment of lower extremity physical function that consists of 3 standing balance tasks held for 10 seconds each (side-by-side, tandem and semi-tandem), two 4-m walk tests to assess usual gait speed, and 5 repeated chair stands. To minimize ceiling effects and maximize overall dispersion of test scores, the eSPPB increases the holding time of the semi- and full-tandem stands to 30 seconds and adds a
Conditions Studied
Study Locations (1)
North Carolina
- Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2018-07-20 |
| Est. Completion | 2023-07-12 |
What the finished NCT03430427 record still lists
NCT03430427 is an observational study that tracks outcomes without assigning an intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, below the 4,050-participant average among 3 other White Matter Disease trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with White Matter Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03430427 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03430427 about?
NCT03430427 is a clinical study titled "Brain Networks and Mobility Function: B-NET". Rapidly accumulating evidence indicates that the central nervous system (CNS) plays a pivotal role in mobility function with age-associated CNS changes strongly contributing to declining mobility. Studies linking the brain to mobility have used anatomical measures like brain volume and white matter ...
What is the current status of trial NCT03430427?
This trial is currently completed. The enrollment target is 192 participants. The study started on 2018-07-20. Estimated completion is 2023-07-12.
What conditions does trial NCT03430427 study?
This clinical trial studies the following conditions: White Matter Disease, Central Nervous System.
Who is sponsoring clinical trial NCT03430427?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03430427 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for White Matter Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI